Showing 1991-2000 of 5771 results for "".
- GenSight Biologics Announces Publication of Results from Lumevoq REVERSE Pivotal Phase 3 Trialhttps://modernod.com/news/gensight-biologics-announces-publication-of-results-from-lumevoq-reverse-pivotal-phase-3-trial/2478644/GenSight Biologics announced that the journal Science Translational Medicine has published results from the REVERSE pivotal phase 3 clinical trial of Lumevoq gene therapy in ND4 Leber Hereditary Optic Neuropathy (LHON) subjects along with key results from a non-human primate stu
- Norlase Announces Newly Appointed Distributors into Major European Marketshttps://modernod.com/news/norlase-announces-newly-appointed-distributors-into-major-european-markets/2478640/Norlase has announced new distributor partnerships developed to advance market growth and global expansion of the Norlase family of green laser systems into France, Germany, Italy, Spain, and the United Kingdom. “We’re thrilled to announce that most ophthalmologists in Europe will no
- Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aldeyra-announces-first-patient-enrolled-in-the-phase-3-tranquility-trial-of-reproxalap-for-the-treatment-of-dry-eye-disease/2478638/Aldeyra Therapeutics announced enrollment of the first patient in the phase 3 TRANQUILITY trial of 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease. The multicenter randomized, double-masked, parallel design, vehicle-controlled clinical trial will assess the effica
- Novaliq Announces First Patient Randomized in the ESSENCE-2 Phase 3 Trial of Dry Eye Treatment CyclASolhttps://modernod.com/news/novaliq-announces-first-patient-randomized-in-the-phase-3-trial-essence-2-of-dry-eye-treatment-cyclasol/2478637/Novaliq announced that it has initiated the randomization of patients in its phase 3 clinical trial ESSENCE-2 that is designed to replicate efficacy results of the previous phase 2/3 ESSENCE-1 trial. “The initiation of this second registrational trial represents a key milestone for b
- RetinAI Announces Collaboration with Novartis to Provide Artificial Intelligence Solutions in Ophthalmologyhttps://modernod.com/news/retinai-announces-collaboration-with-novartis-to-provide-artificial-intelligence-solutions-in-ophthalmology/2478636/RetinAI Medical announced a multi-year collaboration with Novartis Pharma under which RetinAI’s IT solutions and artificial intelligence tools will be used to support multiple projects in ophthalmology and digital health. Financial terms of the deal were not disclosed. The first pro
- Katena Products Announces Steve Blazejewski as New CEOhttps://modernod.com/news/katena-products-announces-steve-blazejewski-as-new-ceo/2478633/Katena Products announced that Steve Blazejewski has joined as Chief Executive Officer. As a seasoned executive, Mr. Blazejewski brings impressive leadership experience and medical device knowledge to Katena. He has previously served as President of Medical Solutions at Cardinal Health and
- Registration Open for International Sports Vision Association 2021 Virtual Annual Conferencehttps://modernod.com/news/registration-open-for-international-sports-vision-association-2021-virtual-annual-conference/2478628/Registration is now open for “Joining Forces to Enhance Athletic Performance,” (www.isva2021.com) the 5th Annual International Sports Vision Association (ISVA) conference. The 2021 conference will be live online on February 20-21, 2021.
- Topcon Announces the US Launch of RDx Telehealth Software Platformhttps://modernod.com/news/topcon-announces-the-us-launch-of-rdx-telehealth-software-platform/2478617/Topcon Healthcare announced that it has launched its new Topcon RDx ocular telehealth software platform in the US market. Topcon RDx is an eye health exam platform that allows practitioners to connect to their office remotely and conduct comprehensive eye exams in real-time from virtual
- TearClear Announces Successful Completion of Pre-IND Meeting With the FDA for a Preservative-Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucomahttps://modernod.com/news/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma/2478608/TearClear announced successful completion of pre-IND (investigational new drug) meeting with the FDA regarding the development plan for the preservative-free multi-dose delivery of a proprietary latanoprost formulation, including the clinical study design for the registration
- Eluminex Biosciences Announces Closing of $50 Million Series A Financinghttps://modernod.com/news/eluminex-biosciences-announces-closing-of-50-million-series-a-financing/2478597/China-based Eluminex Biosciences announced the completion of a $50 million Series A Financing, which will be used to develop a pipeline addressing critical unmet medical needs in vision-threatening diseases for patients. The financing was co-led by Lilly Asia